BPC-157 for IBD Trials: Updated Comprehensive Animal Evidence Supporting Clinical Development
Updated comprehensive review of BPC-157's IBD-relevant evidence: healing colitis, ulcers, fistulas; NO system interactions; prostaglandin modulation; angiogenesis; and clinical trial progression (PL-10, PLD-116, PL14736, Pliva).
Quick Facts
What This Study Found
BPC-157 in IBD clinical trials supported by expanded animal evidence: heals colitis/fistulas/strictures, modulates NO and prostaglandin systems, promotes angiogenesis, and shows cytoprotection across multiple GI inflammation models — updated pre-clinical support for advancing clinical development.
Key Numbers
How They Did This
animal-study study.
Why This Research Matters
Relevant for bpc-157, gut-healing, wound-healing.
The Bigger Picture
Advances peptide research.
What This Study Doesn't Tell Us
See abstract.
Questions This Raises
- ?Further research needed.
- ?Clinical translation to evaluate.
Trust & Context
- Key Stat:
- Key finding BPC-157 in IBD clinical trials supported by expanded animal evidence: heals colitis/fistulas/strictures, modulates NO and prostaglandin systems, promo
- Evidence Grade:
- moderate evidence.
- Study Age:
- Published in 2007.
- Original Title:
- Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL14736, Pliva, Croatia) heals ileoileal anastomosis in the rat.
- Published In:
- Surgery today, 37(9), 768-77 (2007)
- Authors:
- Vuksic, Tihomir(4), Zoricic, Ivan(12), Brcic, Luka(17), Sever, Marko, Klicek, Robert, Radic, Bozo, Cesarec, Vedran, Berkopic, Lidija, Keller, Neike, Blagaic, Alenka Boban, Kokic, Neven, Jelic, Ivan, Geber, Juraj, Anic, Tomislav, Seiwerth, Sven, Sikiric, Predrag
- Database ID:
- RPEP-01302
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
What was studied?
BPC-157 for IBD Trials: Updated Comprehensive Animal Evidence Supporting Clinical Development
What was found?
Updated comprehensive review of BPC-157's IBD-relevant evidence: healing colitis, ulcers, fistulas; NO system interactions; prostaglandin modulation; angiogenesis; and clinical trial progression (PL-10, PLD-116, PL14736, Pliva).
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-01302APA
Vuksic, Tihomir; Zoricic, Ivan; Brcic, Luka; Sever, Marko; Klicek, Robert; Radic, Bozo; Cesarec, Vedran; Berkopic, Lidija; Keller, Neike; Blagaic, Alenka Boban; Kokic, Neven; Jelic, Ivan; Geber, Juraj; Anic, Tomislav; Seiwerth, Sven; Sikiric, Predrag. (2007). Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL14736, Pliva, Croatia) heals ileoileal anastomosis in the rat.. Surgery today, 37(9), 768-77.
MLA
Vuksic, Tihomir, et al. "Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL14736, Pliva, Croatia) heals ileoileal anastomosis in the rat.." Surgery today, 2007.
RethinkPeptides
RethinkPeptides Research Database. "Stable gastric pentadecapeptide BPC 157 in trials for inflam..." RPEP-01302. Retrieved from https://rethinkpeptides.com/research/vuksic-2007-stable-gastric-pentadecapeptide-bpc
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.